In conclusion, Arg metabolic reprogramming plays a dual regulatory role on TAMs through iNOS and ARG pathways, but in immunosuppressive TME of biliary and pancreatic malignancies, ARG1-dominated tumor-promoting effects are dominant. The gene discussed is NOS2; the disease is neoplasm.